VEGFA and wet macular degeneration: The release of bevacizumab—one subtype of an anti-VEGF agent—from the hydrogel was shown to be bioactive for the potential treatment of wet AMD by inhibiting retinal angiogenesis in the eyes of laser-induced photocoagulation Rex rabbits.